In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment
Last week, AstraZeneca took a swing at J&J and AbbVie’s first-generation BTK inhibitor Imbruvica in the blood cancer chronic lymphocytic leukemia with long-term data from a head-to-head trial. But the partners aren’t going down without a fight.
AbbVie and Janssen unveiled pivotal data on Saturday showing that first-line CLL patients who received Imbruvica and AbbVie’s Roche-partnered Venclexta lived longer without disease progression than patients on Gazyva and the chemotherapy chlorambucil. The Phase III GLOW trial enrolled 211 elderly patients, or those with comorbidities or concurrent illnesses. Overall, the median age was 71 years old.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.